biostudies-literatureUnknown13De Sanctis RTo date, only few marine natural compounds have been proved to be active in breast cancer (BC). The main marine-derived drugs that have been studied for the treatment of BC are tubulin-binding agents (eribulin and plocabulin), DNA-targeting agents (cytarabine and minor groove binders-trabectedin and lurbinectedin) and Antibody-Drug Conjugates (ADCs). Notably, eribulin is the only approved cytotoxic drug for the treatment of advanced BC (ABC), while cytarabine has a limited indication in case of leptomeningeal diffusion of the disease. Also plocabulin showed limited activity in ABC but further research is needed to define its ultimate potential role. The available clinical data for both trabectedin and lurbinectedin are of particular interest in the treatment of BRCA-mutated tumours and HR Frontiers in pharmacology909566https://www.ebi.ac.uk/biostudies/studies/S-EPMC9495264biostudies-literatureFrom seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.PMC9495264Zambelli ATancredi RDe Sanctis RGaudio MFranceschini RJacobs FBenvenuti CSantoro APedrazzoli PfalseFrom seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.To date, only few marine natural compounds have been proved to be active in breast cancer (BC). The main marine-derived drugs that have been studied for the treatment of BC are tubulin-binding agents (eribulin and plocabulin), DNA-targeting agents (cytarabine and minor groove binders-trabectedin and lurbinectedin) and Antibody-Drug Conjugates (ADCs). Notably, eribulin is the only approved cytotoxic drug for the treatment of advanced BC (ABC), while cytarabine has a limited indication in case of leptomeningeal diffusion of the disease. Also plocabulin showed limited activity in ABC but further research is needed to define its ultimate potential role. The available clinical data for both trabectedin and lurbinectedin are of particular interest in the treatment of BRCA-mutated tumours and HR 2022-01-01T00:00:00Z20222025-04-05T11:03:37Z2024-11-09T22:26:55.93ZS-EPMC94952643616042210.3389/fphar.2022.909566